Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension

• Published in: Journal of hypertension Vol. 10; no. 7; p. 607
• Main Authors: Bevan, E G, Connell, J M, Doyle, J, Carmichael, H A, Davies, D L, Lorimer, A R, McInnes, G T
• Format: Journal Article
• Language: English
• Published: England 01.07.1992
• Subjects: Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; Atrial Natriuretic Factor - blood; Blood Pressure - drug effects; Double-Blind Method; Female; Humans; Hypertension - drug therapy; Indans - administration & dosage; Indans - therapeutic use; Male; Middle Aged; Neprilysin - antagonists & inhibitors; Propionates - administration & dosage; Propionates - therapeutic use
• ISSN: 0263-6352
• DOI: 10.1097/00004872-199207000-00002

To examine the efficacy and tolerability of the neutral endopeptidase inhibitor, candoxatril (UK 79,300) as monotherapy in essential hypertension. Double-blind, placebo-controlled, parallel-group study of 28 days' duration. Three hospital outpatient departments participating in the Glasgow Blood Pressure Clinic (Glasgow, UK). Forty patients with essential hypertension with diastolic blood pressure 95-114 mmHg after a 2-4 week placebo run-in period. Twenty-eight days' treatment with candoxatril 200 mg twice daily or matching placebo capsules. Changes in supine and erect blood pressure, and volunteered side effects during double-blind treatment. When measured at the end of the dose interval, the fall in supine blood pressure following candoxatril was not significantly greater than that after placebo. Compared with placebo, a significant effect for candoxatril was seen only for systolic blood pressure in the erect posture; the fall in erect diastolic blood pressure attributable to candoxatril was insignificant. Median plasma atrial natriuretic peptide concentration increased in candoxatril-treated patients and decreased in the placebo group. No stimulation of the renin-aldosterone axis was seen. There was a non-significant trend towards greater urinary excretion of cyclic guanosine monophosphate after candoxatril. Mean plasma concentration of candoxatril at (UK 73,967--the active metabolite of candoxatril) reached a peak of 1010 +/- 437 ng/ml after acute dosing, and 1328 +/- 405 ng/ml after chronic dosing; time to maximum concentration was 2 h in each case. Candoxatril was well-tolerated; numbers of adverse events did not differ between active treatment and placebo. Although atrial natriuretic peptide levels were significantly increased, candoxatril 200 mg twice daily for 28 days did not produce a clinically relevant fall in blood pressure. Our results cast some doubt upon the role of neutral endopeptidase inhibition in the treatment of unselected hypertensive patients.